Paclitaxel in self-micro emulsifying formulations: oral  bioavailability study in mice.
The anticancer drug paclitaxel is formulated for i.v. administration in a mixture of Cremophor EL and ethanol.Its oral bioavailability is very low due to the action of P-glycoproteinin the gut wall and CYP450 in gut wall and liver.However, proof-of-concept studies using the i.v. formulation diluted in drinking water have demonstrated the feasibility of the oral route as an alternative when given in combination with inhibitors of P-glycoprotein and CYP450. Because of the unacceptable pharmaceutical properties of the drinking solution, a better formulation for oral application is needed.We have evaluated the suitability of various self-micro emulsifying oily formulations (SMEOF's) of paclitaxel for oral application using wild-type and P-glycoprotein knockout mice and cyclosporin A (CsA) as P-glycoprotein and CYP450 inhibitor. The oral bioavailability of paclitaxel in all SMEOF's without concomitant CsA was low in wild-type mice, showing that this vehicle does not enhance intestinal uptake by itself.Paclitaxel (10 mg/kg) in SMEOF#3 given with CsA resulted in plasma levels that were comparable to the Cremophor ELethanol containing drinking solution plus CsA. Whereas the AUC increased linearly with the oral paclitaxel dose in P-glycoprotein knockout mice, it increased less than proportional in wild-type mice given with CsA. In both strains more unchanged paclitaxel was recovered in the feces at higher doses. This observation most likely reflects more profound precipitation of paclitaxel within the gastro-intestinal tract at higher doses. The resulting absolute reduction in absorption of paclitaxel from the gut was possibly concealed by partial saturation of first-pass metabolism when P-glycoprotein was absent. In conclusion, SMEOF's maybe a useful vehicle for oral delivery of paclitaxel in combination with CsA, although the physical stability within the gastro-intestinal tract remains a critical issue, especially when applied at higher dose levels.
Oostendorp
Roos L
RL
Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands. roosoostendorp@hotmail.com
Buckle
T
T
Lambert
G
G
Garrigue
J S
JS
Beijnen
J H
JH
Schellens
J H M
JH
van Tellingen
O
O
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000172:deficiency / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D004655:Emulsions / Q000737:chemistry*; D005243:Feces; D005260:Female; D051379:Mice; D018345:Mice, Knockout; D017239:Paclitaxel / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004655:Emulsions; D017239:Paclitaxel
Eur J Pharm Sci. 2000 Dec;12(2):103-10
11102737
Transplant Proc. 1993 Apr;25(2):1875
8470210
Br J Cancer. 2001 Nov 16;85(10):1472-7
11720431
Clin Cancer Res. 1998 Oct;4(10):2293-7
9796957
Ann Pharmacother. 1994 May;28(5 Suppl):S11-4
7915152
J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):383-91
7780591
Ann Oncol. 2003 Feb;14(2):197-204
12562644
Br J Cancer. 2006 Oct 9;95(7):794-800
16969354
Clin Pharmacol Ther. 1996 Mar;59(3):297-303
8653992
J Chromatogr B Biomed Appl. 1995 Dec 15;674(2):261-8
8788155
J Clin Oncol. 2000 Jun;18(12):2468-75
10856107
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5
9050899
Lancet. 1998 Jul 25;352(9124):285
9690410
Cancer Res. 1999 Apr 1;59(7):1454-7
10197613
Cancer Invest. 1995;13(4):381-404
7627725
Ann Oncol. 1994;5 Suppl 6:S7-16
7865438
Br J Cancer. 2006 Sep 18;95(6):729-34
16926835
J Clin Oncol. 1997 Jan;15(1):110-5
8996131
Br J Cancer. 1999 Sep;81(2):330-5
10496361
Cancer Res. 1996 May 1;56(9):2112-5
8616858
J Clin Oncol. 2002 Dec 1;20(23):4508-16
12454106
Cancer Chemother Pharmacol. 2002 Feb;49(2):119-25
11862425
Eur J Pharm Biopharm. 2000 Jul;50(1):179-88
10840200
Br J Cancer. 1997;76(9):1181-3
9365166
J Pharmacol Exp Ther. 1995 Nov;275(2):566-75
7473140
J Pharm Sci. 2003 Dec;92(12):2411-8
14603486